Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in ...
Sanofi a annoncé la conclusion d’un accord de licence co-exclusif avec Novavax, une société de biotechnologies basée dans le Maryland aux États-Unis, pour la co-commercialisation d’un vaccin COVID-19 ...
Le français Sanofi a annoncé ce vendredi 10 mai un accord de licence avec l’américain Novavax pour la commercialisation d’un vaccin contre le Covid-19 et le développement de vaccins contre ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has ...
(Boursier.com) — Dans le cadre de l'ambition de Sanofi de développer un portefeuille diversifié de vaccins parmi les meilleurs de leur catégorie, l'entreprise annonce la conclusion d'un ...
, opens new tab on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi (SASY.PA) , opens new tab for its COVID-19 vaccine in exchange for a stake that valued the U.S ...
Sanofi comptabilisera à partir de 2025 les ventes du vaccin adjuvanté contre le COVID-19 de Novavax et prendra à sa charge certaines dépenses de recherches et développement, règlementaires ...